Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Rituximab and multiple sclerosis.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Multiple Sclerosis and Pregnancy: Current Considerations.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Alemtuzumab benefits hard-to-treat MS patients
Rituximab product approval information - Licensing action
Novantrone (mitoxantrone HCl) Injection February 2009
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
RTL therapy for multiple sclerosis: a Phase I clinical study.
American Society for Cell Biology Annual Meeting
UCSF Seminar: "Antibody Repertoire Sequencing"
The INCAT disability score: A critical analysis of its measurement properties.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Society for Neuroscience Annual Meeting
Inflammatory cortical demyelination in early multiple sclerosis.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting

Pages